A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Key Inclusion Criteria: * The activity of the coagulation factor VIII (FVIII:C) \< 1%. * Patients previously treated with FVIII concentrate (s) for a minimum of 150 exposure days (EDs) prior to study entry * Normal prothrombin time or INR \< 1.3 * Negative lupus anticoagulant Key Exclusion Criteria: * Hypersensitive to any of the excipients of the test materials (e.g. allergic to murine or hamster origin heterologous proteins) * History of hypersensitivity or anaphylaxis associated with any FVIII or II immunoglobulin administration * Current FVIII inhibitor-positive or history of FVIII inhibitor-positive * Other coagulation disorder(s) in addition to hemophilia A.• Significant hepatic or renal impairment (ALT and AST \> 2×ULN; serum bilirubin level \> 2 × upper limit of normal (ULN), Urea /BUN \> 2×ULN, Cr \> 176.8 µmol/L) * One or more clinically significant tests for Human Immunodeficiency Virus (HIV), Antisyphilitic spirulina (TPHA) and Hepatitis C Virus (HCV) Antibody * Patients who received any anticoagulant or antiplatelet therapy within one week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials * Patients having major surgery or receiving blood or bood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study * Patients who previously participated in the other clinical trials within one month prior screening * Any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation * Patient who is considered by the other investigators not suitable for clinical study Other protocol-defined inclusion/exclusion Criteria May Apply.